Navigating Advances in the Treatment of Pulmonary Arterial Hypertension: Understanding Multidisciplinary Approaches to Optimize Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2021 – August 1, 2022
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Actelion Pharmaceuticals, a Janssen Pharmaceutical Company of Johnson & Johnson,
and Bayer Healthcare

Description:
Pulmonary Arterial Hypertension (PAH) is a progressive vascular disorder characterized by vascular remodeling of the pulmonary arteries which carry blood from the heart to the lungs. For those with PAH, the muscles within the arterial walls tighten, which can cause thickening and/or scar tissue to develop, increasingly narrowing their diameter. This leads to a progressive increase in pulmonary vascular resistance that leads to right ventricular failure and significant morbidity and mortality. Over time, the heart muscle can become so weakened that its ability to pump enough blood through the body is lost, leading to heart failure. The estimated prevalence is between 15 and 50 cases per million individuals and about half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis – and even with aggressive management, PAH has a 15% annual mortality rate.

There continue to be significant challenges in identifying and diagnosing PAH because it requires a combination of information based on symptoms, a physician examination, risk factors, and other findings based on previous tests. Evaluation to detect the presence of PAH requires a comprehensive set of tests, which typically include laboratory testing, echocardiography, pulmonary function testing, assessment of exercise capacity with six-minute walk distance or cardiopulmonary exercising testing, imaging, nocturnal oximetry and/or overnight polysomnography, and right heart catheterization. These extensive tests are crucial in determining the severity of PAH and the appropriate treatment strategies for patients on an individual basis, driven by a provider’s knowledge of each patient’s specific needs.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden, disease characteristics, and guidelines in the management of pulmonary arterial hypertension (PAH)

  • Identify who is at risk for pulmonary hypertension and effectively diagnose patients

  • Assess combination or triple combination treatment strategies for PAH based on clinical trials and real-world data

  • Analyze emerging and novel therapies to understand their impact on PAH treatments

  • Implement a multidisciplinary team approach to effectively manage treatment, adherence, and adverse events

     

Faculty: Richard N. Channick, MD
Saul Brandman Endowed Chair in Pulmonary Arterial Hypertension
Co-Director, Pulmonary Vascular Disease Program
Director, Acute and Chronic Thromboembolic Disease Program
Professor of Medicine, Pulmonary and Critical Care Division
David Geffen School of Medicine at UCLA

Disclosure:

Dr. Channick has spoken for Bayer and Janssen. Dr. Channick has served as a consultant for Janssen, Bayer, Third Pole, and Gossamer.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Actelion Pharmaceuticals, a Janssen Pharmaceutical Company of Johnson & Johnson,
and Bayer Healthcare

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue